Providing β-lactams a helping hand: Targeting the AmpC β-lactamase induction pathway

Future Microbiology

Volumn 6, Issue 12, 2011, Pages 1415-1427

  Mark, Brian L ^a   Vocadlo, David J ^b   Oliver, Antonio ^c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

lactam; lactamase; AmpC; AmpG; AmpR; Antibiotic resistance; Cystic fibrosis; FtsZ; NagZ; Pseudomonas aeruginosa

Indexed keywords

AVIBACTAM; AZTREONAM; BACTERIAL PROTEIN; BAL 30376; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; CEPHEM; CLAVULANIC ACID; FTSZ PROTEIN; GLYCOSIDASE INHIBITOR; MONOBACTAM; N ACETYL BETA GLUCOSAMINIDASE; N ACETYLGLUCOSAMINE; O (2 ACETAMIDO 2 DEOXY DEXTRO GLUCOPYRANOSYLIDENE)AMINO N PHENYLCARBAMATE; PIPERACILLIN; PROTEIN AMPG; PROTEIN AMPR; PROTEIN NAGZ; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLMURAMIC ACID;

AEROMONAS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL VIRULENCE; BINDING AFFINITY; BINDING SITE; CELL DEATH; CHROMOSOME MUTATION; CRYSTAL STRUCTURE; CYSTIC FIBROSIS; CYTOLYSIS; DRUG POTENCY; DRUG TARGETING; ENZYME SYNTHESIS; GENE EXPRESSION; GENE INACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; LOSS OF FUNCTION MUTATION; LUNG INFECTION; NONHUMAN; OPERON; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; ENTEROBACTERIACEAE; GENE EXPRESSION; HUMANS; MUTATION; PEPTIDOGLYCAN; PSEUDOMONAS AERUGINOSA;

EID: 82455192469     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.128     Document Type: Article

References (90)

1. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to beta lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105(2), 395-424 (2005).
2. Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12(5), 476-481 (2009).
3. Bush K, Jacoby GA. Updated functional classification of {beta} lactamases. Antimicrob. Agents Chemother. 54(3), 969-976 (2010).
4. Ambler RP. The Structure of β lactamases. Phil. Trans. R. Soc. Lond. β Biol. Sci. 289(1036), 321-331 (1980).
5. Jaurin B, Grundström T. AmpC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta lactamases of the penicillinase type. Proc. Natl Acad. Sci. 78(8), 4897-4901 (1981).
6. Jacoby GA. AmpC beta lactamases. Clin. Microbiol. Rev. 22(1), 161-182 (2009).
7. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22(4), 582-610 (2009).
8. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15(2), 194-222 (2002).
9. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168(8), 918-951 (2003).
10. De Vrankrijker AMM, Wolfs TFW, Van Der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatr. Respir. Rev. 11(4), 246-254 (2010).
11. Bebrone C, Lassaux P, Vercheval L et al. Current challenges in antimicrobial chemotherapy: focus on β lactamase inhibition. Drugs 70(6), 651-679 (2010).
12. Livermore DM, Akova M, Wu PJ, Yang YJ. Clavulanate and β lactamase induction. J. Antimicrob. Chemother. 24 (Suppl. B), 23-33 (1989).
13. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. J. Antimicrob. Chemother. 43(4), 882-889 (1999).
14. Drawz SM, Bonomo RA. Three decades of beta lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160-201 (2010).
15. Powers RA, Blázquez J, Weston GS, Shoichet BK, Morosini M-I, Baquero F. The complexed structure and antimicrobial activity of a non-β lactam inhibitor of AmpC β lactamase. Protein Sci. 8(11), 2330-2337 (1999).
16. Bonnefoy A, Dupuis-Hamelin C, Steier VR et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β lactam β lactamase inhibitor. J. Antimicrob. Chemother. 54(2), 410-417 (2004).
17. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J. Antimicrob. Chemother. 65(11), 2382-2395 (2010).
18. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. Stability of FR264205 against AmpC β lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30(5), 443-445 (2007).
19. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against β lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54(3), 1213-1217 (2010).
20. Park JT, Uehara T. How bacteria consume their own exoskeletons (turnover and recycling of cell wall peptidoglycan). Microbiol. Mol. Biol. Rev. 72(2), 211-227, (2008).
21. Livermore DM. β lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8(4), 557-584 (1995).
22. Asgarali A, Stubbs KA, Oliver A, Vocadlo DJ, Mark BL. Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal β lactam resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(6), 2274-2282 (2009).
23. Zamorano L, Reeve TM, Deng L et al. NagZ inactivation prevents and reverts β lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54(9), 3557-3563 (2010).
24. Zamorano L, Reeve TM, Juan C et al. AmpG Inactivation restores susceptibility of pan-beta lactam resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 55(5), 1990-1996 (2011).
25. Holtje J-V. Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli. Microbiol. Mol. Biol. Rev. 62(1), 181-203 (1998).
26. Vollmer W, Holtje JV. Morphogenesis of Escherichia coli. Curr. Opin. Microbiol. 4(6), 625-633 (2001).
27. Höltje J-V. From growth to autolysis: the murein hydrolases in Escherichia coli. Arch. Microbiol. 164(4), 243-254 (1995).
28. Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta lactam resistance in Gram-negative bacteria. Cell 88(6), 823-832 (1997).
29. Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta lactamase induction. EMBO J. 13(19), 4684-4694 (1994).
30. Vollmer W, Joris B, Charlier P, Foster S. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. Rev. 32(2), 259-286 (2008).
31. Cheng Q, Park JT. Substrate specificity of the AmpG permease required for recycling of cell wall anhydro-muropeptides. J. Bacteriol. 184(23), 6434-6436 (2002).
32. Dietz H, Pfeifle D, Wiedemann B. Location of N-acetylmuramyl-l-alanyl-D- glutamylmesodiaminopimelic acid, presumed signal molecule for beta lactamase induction, in the bacterial cell. Antimicrob. Agents Chemother. 40(9), 2173-2177 (1996).
33. Cheng Q, Li H, Merdek K, Park JT. Molecular characterization of the beta-N-acetylglucosaminidase of Escherichia coli and its role in cell wall recycling. J. Bacteriol. 182(17), 4836-4840 (2000).
34. Votsch W, Templin MF. Characterization of a b-N-acetylglucosaminidase of Escherichia coli and elucidation of its role in muropeptide recycling and beta lactamase induction. J. Biol. Chem. 275(50), 39032-39038 (2000).
35. Dietz H, Pfeifle D, Wiedemann B. The signal molecule for beta lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide. Antimicrob. Agents Chemother. 41(10), 2113-2120 (1997).
36. Templin MF, Ursinus A, Holtje JV. A defect in cell wall recycling triggers autolysis during the stationary growth phase of Escherichia coli. EMBO J. 18(15), 4108-4117 (1999).
37. Bartowsky E, Normark S. Purification and mutant analysis of Citrobacter freundii AmpR, the regulator for chromosomal AmpC beta lactamase. Mol. Microbiol. 5(7), 1715-1725 (1991).
38. Lindquist S, Lindberg F, Normark S. Binding of the Citrobacter freundii AmpR regulator to a single DNA site provides both autoregulation and activation of the inducible ampC beta lactamase gene. J. Bacteriol. 171(7), 3746-3753 (1989).
39. Holtje JV, Kopp U, Ursinus A, Wiedemann B. The negative regulator of beta lactamase induction AmpD is a N-acetyl-anhydromuramyl-l-alanine amidase. FEMS Microbiol. Lett. 122(1-2), 159-164 (1994).
40. Jacobs C, Joris B, Jamin M et al. AmpD, essential for both beta lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-l- alanine amidase. Mol. Microbiol. 15(3), 553-559 (1995).
41. Juan C, Gutiérrez O, Oliver A, Ayestarán JI, Borrell N, Pérez JL. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infec. 11(11), 887-892 (2005).
42. Giwercman B, Lambert P, Rosdahl V, Shand G, Hoiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta lactamase producing strains. J. Antimicrob. Chemother. 26(2), 247-259 (1990).
43. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288(5469), 1251-1254 (2000).
44. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 51(11), 4062-4070 (2007).
45. Hocquet D, Berthelot P, Roussel-Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51(10), 3531-3536 (2007).
46. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a spanish multicenter study. Antimicrob. Agents Chemother. 55(5), 1906-1911 (2011).
47. Kaneko K, Okamoto R, Nakano R, Kawakami S, Inoue M. Gene mutations responsible for overexpression of AmpC beta lactamase in some clinical isolates of Enterobacter cloacae. J. Clin. Microbiol. 43(6), 2955-2958 (2005).
48. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. Molecular mechanisms of beta lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49(11), 4733-4738 (2005).
49. Lindberg F, Lindquist S, Normark S. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii beta lactamase. J. Bacteriol. 169(5), 1923-1928 (1987).
50. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103(22), 8487-8492 (2006).
51. Juan C, Moya B, Perez JL, Oliver A. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50(5), 1780-1787 (2006).
52. Moya B, Juan C, Alberti S, Perez JL, Oliver A. Benefit of having multiple ampD genes for acquiring β lactam resistance without losing fitness and virulence of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52(10), 3694-3700 (2008).
53. Schmidtke AJ, Hanson ND. Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52(11), 3922-3927 (2008).
54. Moya B, Dotsch A, Juan C et al. Beta lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 5(3), e1000353 (2009).
55. Kuga A, Okamoto R, Inoue M. ampR gene mutations that greatly increase class C beta lactamase activity in Enterobacter cloacae. Antimicrob. Agents Chemother. 44(3), 561-567 (2000).
56. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N. Constitutive high expression of chromosomal beta lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46(11), 3406-3411 (2002).
57. Kong KF, Jayawardena SR, Indulkar SD et al. Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB beta lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob. Agents Chemother. 49(11), 4567-4575 (2005).
58. Gutierrez O, Juan C, Cercenado E et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from spanish hospitals. Antimicrob. Agents Chemother. 51(12), 4329-4335 (2007).
59. Livermore DM. Interplay of impermeability and chromosomal beta lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36(9), 2046-2048 (1992).
60. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50(5), 1633-1641 (2006).
61. Beer D, Maloisel JL, Rast DM, Vasella A. Synthesis of 2-acetamido-2-deoxy-d-gluconhydroximolactone-derived and chitobionhydroximolactone-derived N-phenylcarbamates, potential inhibitors of beta-N-acetylglucosaminidase. Helv. Chim. Acta 73(7), 1918-1922 (1990).
62. Stubbs KA, Balcewich M, Mark BL, Vocadlo DJ. Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta lactam resistance. J. Biol. Chem. 282(29), 21382-21391 (2007).
63. Vocadlo DJ, Mayer C, He S, Withers SG. Mechanism of action and identification of Asp242 as the catalytic nucleophile of Vibrio furnisii N-acetyl-beta-d-glucosaminidase using 2-acetamido-2-deoxy-5-fluoro-alpha-l- idopyranosyl fluoride. Biochemistry 39(1), 117-126 (2000).
64. Stubbs KA, Scaffidi A, Debowski AW, Mark BL, Stick RV, Vocadlo DJ. Synthesis and use of mechanism-based protein-profiling probes for retaining beta-d-glucosaminidases facilitate identification of Pseudomonas aeruginosa NagZ. J. Am. Chem. Soc. 130(1), 327-335 (2008).
65. Vocadlo DJ, Davies GJ. Mechanistic insights into glycosidase chemistry. Curr. Opin. Chem. Biol. 12(5), 539-555 (2008).
66. Vocadlo DJ, Withers SG. Detailed Comparative analysis of the catalytic mechanisms of beta-N-acetylglucosaminidases from families 3 and 20 of glycoside hydrolases. Biochemistry 44(38), 12809-12818 (2005).
67. Tews I, Perrakis A, Oppenheim A, Dauter Z, Wilson KS, Vorgias CE. Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease. Nat. Struct. Biol. 3(7), 638-648 (1996).
68. Mark BL, Vocadlo DJ, Knapp S, Triggs-Raine BL, Withers SG, James MN. Crystallographic evidence for substrate-assisted catalysis in a bacterial beta-hexosaminidase. J. Biol. Chem. 276(13), 10330-10337 (2001).
69. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MN. Crystallographic structure of human beta-hexosaminidase A. Interpretation of Tay-Sachs mutations and loss of G(M2) ganglioside hydrolysis. J. Mol. Biol. 359(4), 913-929 (2006).
70. Dennis RJ, Taylor EJ, Macauley MS et al. Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity. Nat. Struct. Mol. Biol. 13(4), 365-371 (2006).
71. Balcewich MD, Stubbs KA, He Y et al. Insight into a strategy for attenuating AmpC-mediated beta lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ. Protein Sci. 18(7), 1541-1551 (2009).
72. Lindquist S, Weston-Hafer K, Schmidt H et al. AmpG, a signal transducer in chromosomal beta lactamase induction. Mol. Microbiol. 9(4), 703-715 (1993).
73. Schmidt H, Korfmann G, Barth H, Martin H. The signal transducer encoded by ampG is essential for induction of chromosomal AmpC beta lactamase in Escherichia coli by beta lactam antibiotics and 'unspecific' inducers. Microbiology 141(Pt 5), 1085-1092 (1995).
74. Zhang Y, Bao Q, Gagnon L et al. ampG gene of Pseudomonas aeruginosa and its role in beta lactamase expression. Antimicrob. Agents Chemother. 54(11), 4772-4779 (2010).
75. Kong K-F, Aguila A, Schneper L, Mathee K. Pseudomonas aeruginosa beta lactamase induction requires two permeases, AmpG and AmpP. BMC Microbiol. 10(1), 328 (2010).
76. Scheurwater E, Reid CW, Clarke AJ. Lytic transglycosylases: bacterial space-making autolysins. Int. J. Biochem. Cell Biol. 40(4), 586-591 (2008).
77. Korsak D, Liebscher S, Vollmer W. Susceptibility to antibiotics and beta lactamase induction in murein hydrolase mutants of Escherichia coli. Antimicrob. Agents Chemother. 49(4), 1404-1409 (2005).
78. Balcewich MD, Reeve TM, Orlikow EA, Donald LJ, Vocadlo DJ, Mark BL. Crystal structure of the ampr effector binding domain provides insight into the molecular regulation of inducible AmpC β lactamase. J. Mol. Biol. 400(5), 998-1010 (2010).
79. Erickson HP, Anderson DE, Osawa M. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol. Mol. Biol. Rev. 74(4), 504-528 (2010).
80. Young KD. Bacterial shape: two-dimensional questions and possibilities. Annu. Rev. Microbiol. 64(1), 223-240 (2010).
81. Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Med. Chem. 2(8), 1305-1323 (2010).
82. Kapoor S, Panda D. Targeting FtsZ for antibacterial therapy: a promising avenue. Expert Opin. Ther. Targets 13(9), 1037-1051 (2009).
83. Haydon DJ, Stokes NR, Ure R et al. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321(5896), 1673-1675 (2008).
84. Ottolenghi AC, Ayala JA. Induction of a class I beta lactamase from Citrobacter freundii in Escherichia coli requires active ftsZ but not ftsA or ftsQ products. Antimicrob. Agents Chemother. 35(11), 2359-2365 (1991).
85. Uehara T, Park JT. Role of the murein precursor UDP-N-acetylmuramyl-l- Ala-gamma-d-Glu-meso-diaminopimelic acid-d-Ala-d-Ala in repression of beta lactamase induction in cell division mutants. J. Bacteriol. 184(15), 4233-4239 (2002).
86. Beuria TK, Santra MK, Panda D. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 44(50), 16584-16593 (2005).
87. Niumsup P, Simm AM, Nurmahomed K, Walsh TR, Bennett PM, Avison MB. Genetic linkage of the penicillinase gene, amp, and blrAB, encoding the regulator of β lactamase expression in Aeromonas spp. J. Antimicrob. Chemother. 51(6), 1351-1358 (2003).
88. Uehara T, Suefuji K, Valbuena N, Meehan B, Donegan M, Park JT. Recycling of the anhydro-N-acetylmuramic acid derived from cell wall murein involves a two-step conversion to N-acetylglucosamine-phosphate. J. Bacteriol. 187(11), 3643-3649 (2005).
89. Jaeger T, Arsic M, Mayer C. Scission of the lactyl ether bond of N-acetylmuramic acid by Escherichia coli "etherase". J. Biol. Chem. 280(34), 30100-30106 (2005).
90. Bacik J-P, Whitworth GE, Stubbs KA et al. Molecular basis of 1,6-anhydro bond cleavage and phosphoryl transfer by Pseudomonas aeruginosa 1,6-anhydro-N-acetylmuramic acid kinase. J. Biol. Chem. 286(14), 12283-12291 (2011).